Anuh Pharma Limited
2,800words
7turns
0analyst exchanges
0executives
Key numbers — 40 extracted
rs,
₹199.54 crore
₹670.97 crore
₹659.10 crore
27.61%
₹15.73 crore
₹20.07 crore
₹70.36 crore
₹87.25 crore
30.26%
₹17.28 crore
₹13.27 crore
Guidance — 4 items
ROCE
opening
“For the financial year ending FY25, the company recorded a Return on Capital Employed (ROCE) of 18.85%, reflecting sound and robust efficiency in the utilization of working capital and overall capital employed.”
Business highlights
opening
“In FY25, Anuh Pharma’s overall customer base increased from 698 to 737, indicating a notable expansion in market reach.”
Business highlights
opening
“We expect to add 5 to 6 new products in FY 2026, contributing to revenue growth and business expansion.”
Strategic Growth Outlook
opening
“The expansion project with state of the art manufacturing facility targeted at regulated market is completed and commercial production from the said new facility started w.e.f.”
Advertisement
Risks & concerns — 2 flagged
For the full financial year ended 31st March 2025, the company reported a PBT of ₹61.00 crore, as against ₹78.31 crore in the previous year, representing a decline of 22.10%.
— Profit Before Tax
He has been a Director several large listed Corporations in India and has had major contribution as Chairman / Member of Audit Committee, Risk Management, Nomination & Remuneration, ESG/CSR, etc.
— Market leadership
Speaking time
1
1
1
1
1
1
1
Advertisement
Opening remarks
Revenue Growth
For the fourth quarter, Company has recorded its highest‐ever quarterly revenue of ₹199.54 crore, marking a historic milestone for the company. For the full financial year, the total revenue stood at ₹670.97 crore, reflecting a growth compared to ₹659.10 crore reported in the previous year.
EBIDTA Margin
The EBITDA for the fourth quarter improved significantly by 27.61%, rising from ₹15.73 crore to ₹20.07 crore, underscoring enhanced operational efficiency and performance. However, for the full financial year, EBITDA stood at ₹70.36 crore, compared to ₹87.25 crore in the previous year, reflecting the impact of external market and cost factors during the earlier part of the year.
Profit Before Tax
Our company has demonstrated strong sequential growth in profitability, with Profit Before Tax (PBT) for the fourth quarter ended 31st March 2025 increased by 30.26% to ₹17.28 crore, compared to ₹13.27 crore in the previous quarter. This improvement reflects the company’s continued focus on operational efficiency and cost management. For the full financial year ended 31st March 2025, the company reported a PBT of ₹61.00 crore, as against ₹78.31 crore in the previous year, representing a decline of 22.10%. The annual performance was impacted by challenges in the initial quarters, but the company remains confident in its long‐term growth trajectory and strategic initiatives.
ROCE
For the financial year ending FY25, the company recorded a Return on Capital Employed (ROCE) of 18.85%, reflecting sound and robust efficiency in the utilization of working capital and overall capital employed. 5 Message from Joint MD
Business highlights
In FY25, Anuh Pharma’s overall customer base increased from 698 to 737, indicating a notable expansion in market reach. Notably, the export customer base grew from 260 to 304, reflecting strong diversification and deeper penetration into international markets. We currently manufacture 40 APIs, including 6 introduced this financial year. We expect to add 5 to 6 new products in FY 2026, contributing to revenue growth and business expansion. To support this, manufacturing capacity has increased from 1,800 MT to 2,200 MT, strengthening our portfolio and market presence. Additionally, we plan to expand Intermediate manufacturing capacity by 300 MTPA in FY 2026 to improve efficiency, meet demand, and support new product launches.
Strategic Growth Outlook
Moving forward, Anuh Pharma’s growth strategy relies on market expansion, the addition of new products, and inorganic growth opportunities. The future of Active Pharmaceutical Ingredients (API) lies in innovation and the development of complex chemistry products, with a particular focus on lifestyle drugs addressing conditions such as diabetes, hypertension, and obesity. Leveraging the strength of our experienced team and the robust resources available in Research & Development and marketing, we are well‐positioned to achieve significant growth. The company anticipates a steady growth rate of 15‐16% per annum. We extend our heartfelt gratitude to you, our investors, for your continued trust and partnership. Your support is a driving force behind our accomplishments, and we are committed to realizing even greater numerical milestones together. Ritesh Shah (Joint MD) Vivek Shah (Joint MD) 6 Financial performance highlights (last 5 years) Total Revenue (INR in Cr.) EBITDA (INR in Cr.) 44
Advertisement